[{"orgOrder":0,"company":"Tetherex Pharmaceuticals","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Single-Cycle Adenovirus Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tetherex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tetherex Pharmaceuticals \/ Tetherex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Tetherex Pharmaceuticals \/ Tetherex Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Tetherex Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19. The Phase 1 open label study, designed to assess safety, reactogenicity and immunogenicity of the single-cycle...

                          Brand Name : SC-Ad6-1

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 06, 2021

                          Lead Product(s) : Single-Cycle Adenovirus Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Mayo Clinic

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank